Drugs / Odatroltide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04091945 Comparator | Jan 2020 → Feb 2021 | ischemic stroke | Lumosa Therapeutics Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Odatroltide | “PURPOSE: Odatroltide (LT3001), a novel small synthetic peptide molecule designed to recanalize occluded blood vessels and reduce reperfusion injury, is safe and efficacious in...” PMID 38859883 ↗ Jun 2024 |
| Known as | LT3001 | “PURPOSE: Odatroltide (LT3001), a novel small synthetic peptide molecule designed to recanalize occluded blood vessels and reduce reperfusion injury, is safe and efficacious in...” PMID 38859883 ↗ Jun 2024 |
| Modality | Peptide | “a novel small synthetic peptide molecule” PMID 38859883 ↗ Jun 2024 |
| Route | Intravenous | “This study aimed to investigate the safety and tolerability of intravenous administration of odatroltide in patients with acute ischemic stroke within 24 hours of onset.” PMID 38859883 ↗ Jun 2024 |